Prognostické faktory karcinomu děložního hrdla
[Prognostic factors for cervical cancer]
Language Czech Country Czech Republic Media print
Document type English Abstract, Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
23718666
DOI
10.14735/amko201383
PII: 40616
- MeSH
- Humans MeSH
- Biomarkers, Tumor analysis MeSH
- Uterine Cervical Neoplasms diagnosis pathology MeSH
- Prognosis MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- English Abstract MeSH
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Biomarkers, Tumor MeSH
Standardized gynecological oncological therapeutical guidelines are based on ordinary predictive factors, such as depth of stromal invasion, histopathological type of tumor, lymphovascular space invasion, lymph node metastases. Unfortunately, the power of these prognostic factors is not able to determine the safety of this procedure in the relation to disease recurrence in a group of patients who are indicated for conservative operations. This is the appropriate area for new, especially biomolecular prognostic factors (proteins: p63, TAp63, p16, p21, p27, COX-2, genes: hTERC, MYCC). Moreover, comprehensive evaluation of cervical cancer prognostic factors and assessment of new biomarkers of cancer can ease prediction of risk of spread outside primary localization and determine probability of disease recurrence. This information can help to individualize surgical, radiotherapeutic and chemotherapeutic treatment.
References provided by Crossref.org